CDKN2A and nonpapillary renal cell carcinoma: Here we show CNVs of several genes that are associated with sensitivity and resistance to commonly used TKIs and mTORi in ccRCC, including ADCYAP1 loss and GNAS gain associated with sensitivity and resistance and to Cabozantinib, respectively; ACRBP gain and CTBP1 loss were associated with sensitivity and resistance and to Pazopanib, respectively; SULT1A3 gain and CDKN2A loss associated with resistance and sensitivity to the temsirolimus, respectively; CCNE1 gain associated with resistance to Axitinib, and LRP10 loss associated with resistance to Sunitinib.